CD8A and neoplasm: While SBRT alone was insufficient to generate tumor antigens, the combination treatment activated CD8+ T cells and modulated cytokine profiles-decreasing IL-4, IL-6, and IL-10, while increasing IFN-γ, granzyme B, and CCL5.